Curated News
By: NewsRamp Editorial Staff
May 13, 2026

SureNano Science Enters GLP-1 Race with Novel Triple Agonist

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • SureNano Science's GEP-44 triple agonist peptide could outperform first-generation GLP-1 therapies, offering a competitive edge in obesity and metabolic disease markets.
  • GEP-44 targets GLP-1 and Y1/Y2 receptors, with potential oral, sublingual, and intranasal delivery, improving tolerability and efficacy over current treatments.
  • SureNano's GEP-44 aims to improve obesity and diabetes care with better tolerability and non-injectable options, enhancing quality of life for millions.
  • SureNano's GEP-44 is a triple agonist licensed from Syracuse University, targeting multiple receptors to address GLP-1 therapy limitations.

Impact - Why it Matters

This news matters because obesity and metabolic diseases affect hundreds of millions globally, and current GLP-1 therapies have limitations in tolerability and delivery. SureNano's GEP-44, with its triple agonist mechanism and potential for non-injectable delivery, could offer a more patient-friendly and effective treatment option. If successful, it may disrupt the booming weight-loss drug market, providing alternatives that improve compliance and outcomes. For investors, SureNano represents a high-risk, high-reward microcap play in a sector dominated by pharma giants.

Summary

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has captured attention in the rapidly expanding GLP-1 market, as highlighted in recent BioMedWire editorial coverage. The company, through its subsidiary GlucaPharm Inc., is developing GEP-44, a patented triple agonist peptide licensed from Syracuse University. GEP-44 targets GLP-1 and peptide YY receptors Y1 and Y2, aiming to overcome limitations of first-generation GLP-1 therapies such as efficacy, tolerability, and delivery flexibility. This positions SureNano as an emerging microcap player in the obesity and metabolic disease space, alongside established giants like Merck & Co. (NYSE: MRK), AbbVie (NYSE: ABBV), and up-and-comers like Viking Therapeutics (NASDAQ: VKTX) and Altimmune (NASDAQ: ALT).

SureNano’s broader platform strategy includes evaluating oral, sublingual, and intranasal delivery approaches, as well as early-stage formulation and delivery technologies that could expand its therapeutic scope. The company has acquired GlucaPharm Inc. to advance GEP-44, a next-generation peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery. Additionally, SureNano continues its legacy business of distributing the SureNano(TM) surfactant, a food-grade compound for nanoemulsions, under exclusive licenses in Canada, Oklahoma, and Colorado.

InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, syndicated this editorial to a wide audience. The coverage underscores the accelerating momentum across the obesity, diabetes, and cardiometabolic treatment landscape, with SureNano aiming to address significant unmet needs. For more details, visit the full press release at https://ibn.fm/2NGrw.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, SureNano Science Enters GLP-1 Race with Novel Triple Agonist

blockchain registration record for this content.